TopoTarget A/S
Symbion
Fruebjergvej 3 DK 2100 Copenhagen Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com
To NASDAQ OMX Copenhagen A/S
Announcement No. 36-08 / Copenhagen, 30 December 2008
TopoTarget Publishes Financial Calendar for 2009
Copenhagen, Denmark - 30 December, 2008 - TopoTarget A/S (OMX: TOPO) expects to
publish financial reports on the following dates over the next 12 months:
--------------------------------------------------------------------------------
| Annual report for 2008 | 19 March 2009 |
--------------------------------------------------------------------------------
| Financial report for the first quarter of 2009 | 14 May 2009 |
--------------------------------------------------------------------------------
| Financial report for the first half of 2009 | 19 August 2009 |
--------------------------------------------------------------------------------
| Financial report for the third quarter of 2009 | 19 November 2009 |
--------------------------------------------------------------------------------
The company's next Annual General Meeting is planned for 21 April 2009.
TopoTarget A/S
For further information, please contact:
Ulla Hald Buhl
Director IR & Communications
Telephone +45 39 17 83 92
Mobile +45 21 70 10 49
Background information
About TopoTarget
TopoTarget (OMX: TOPO) is an international biotech company headquartered in
Denmark, dedicated to finding ''Answers for Cancer'' and developing improved
cancer therapies. The company was founded and is run by clinical cancer
specialists and combines years of hands-on clinical experience with in-depth
understanding of the molecular mechanisms of cancer.
TopoTarget has a broad clinical pipeline but is currently focusing on the
development of belinostat which has shown proof of concept as monotherapy in
treating haematological malignancies and positive results in solid tumours where
it can be used in combination with full doses of chemotherapy. TopoTarget's
expertise in translational research is utilizing its highly predictive in vivo
and in vitro cancer models. TopoTarget is directing its efforts on key cancer
targets including HDACi, NAD+, mTOR, FasLigand and topoisomerase II inhibitors.
The company's first marketed product Savene®/Totect® was approved by EMEA in
2006 and the FDA in 2007 and is marketed by TopoTarget's own sales force in
Europe and the US. For more information, please refer to www.topotarget.com.
TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical trials
and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. TopoTarget cautions investors that
there can be no assurance that actual results or business conditions will not
differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
TopoTarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of competing
products and technologies; technological uncertainty and product development
risks; uncertainty of additional funding; TopoTarget's history of incurring
losses and the uncertainty of achieving profitability; TopoTarget's stage of
development as a biopharmaceutical company; government regulation; patent
infringement claims against TopoTarget's products, processes and technologies;
the ability to protect TopoTarget's patents and proprietary rights;
uncertainties relating to commercialization rights; and product liability
expo-sure; We disclaim any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events, or otherwise, unless required by law.
